• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NTI 1.28% 7.7¢

NEUROTECH INTERNATIONAL LIMITED - Corporate Spotlight

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

No Corporate Spotlight currently available.

(20min delay)
Last
7.7¢
Change
-0.001(1.28%)
Mkt cap ! $78.33M
Open High Low Value Volume
7.9¢ 8.1¢ 7.7¢ $54.26K 684.2K

Buyers (Bids)

No. Vol. Price($)
3 98220 7.7¢
 

Sellers (Offers)

Price($) Vol. No.
7.9¢ 21369 1
View Market Depth
Last trade - 15.59pm 22/07/2024 (20 minute delay) ?
Last
7.7¢
  Change
-0.001 ( 2.53 %)
Open High Low Volume
7.8¢ 8.1¢ 7.7¢ 203193
Last updated 15.59pm 22/07/2024 ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.